GPC
37
-3
NRG
40
3
IP
54
-2
HSY
38
-7
BA
65
2
MAR
65
2
JCI
51
4
DAL
64
2
FIS
50
4
CFG
48
-2
RIG
54
7
MRK
25
-5
VFC
56
3
BBY
48
2
APA
37
2
PNW
59
-4
EXPD
39
-11
NDAQ
56
4
UPS
51
-4
PAYX
47
-3
GPC
37
-3
NRG
40
3
IP
54
-2
HSY
38
-7
BA
65
2
MAR
65
2
JCI
51
4
DAL
64
2
FIS
50
4
CFG
48
-2
RIG
54
7
MRK
25
-5
VFC
56
3
BBY
48
2
APA
37
2
PNW
59
-4
EXPD
39
-11
NDAQ
56
4
UPS
51
-4
PAYX
47
-3
Financhill
Back

Tarsus Pharmaceuticals 10K Form

Buy
68

TARS
Tarsus Pharmaceuticals

Last Price:
51.15
Seasonality Move:
13.83%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TARS News And Ratings

See the #1 stock for the next 7 days that we like better than TARS

TARS Financial Statistics

Sales & Book Value

Annual Sales: $17.45M
Cash Flow: $-8.93M
Price / Cash Flow: 0
Annual Sales: $6.22
Price / Book: 8.22

Profitability

EPS (TTM): -3.81000
Net Income (TTM): $-134.34M
Gross Margin: $15.85M
Return on Equity: -57.14%
Return on Assets: -41.05%

Tarsus Pharmaceuticals Earnings Forecast

Key Tarsus Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 4 years for TARS is 90.87%.
  • The Selling, General & Administrative Expenses for TARS have been equal to 623.03% of Gross Profit Margin.
  • The Research & Development expenses have been 288.37% of Revenue.
  • The Interest Expense is -2.37% of Operating Income.
  • The Net Earning history of TARS is -778.89% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Tarsus Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TARS
Website: tarsusrx.com

Debt

Debt-to-Equity Ratio: 0.3
Current Ratio: 5.42
Quick Ratio: 5.27

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TARS Technical Analysis vs Fundamental Analysis

Buy
68
Tarsus Pharmaceuticals (TARS) is a Buy

Is Tarsus Pharmaceuticals a Buy or a Sell?